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C140 Case reportAcquired protein C deficiency in a child with acute
myelogenous leukemia, splenic, renal, and
intestinal infarction
Roula A. Faraha, Khalil S. Jalkhb, Hussein Z. Farhatc, Paul E. Sayadd and
Adel M. KadrieWe report the case of a 6-year-old boy diagnosed with acute
promyelocytic leukemia (AML-M3V) when he presented
with pallor, abdominal pain, anorexia, and fatigue. Induction
chemotherapy was started according to the AML-BFM 98
protocol along with Vesanoid (ATRA, All-trans retinoic acid).
On the sixth day of induction, he developed splenic and
gallbladder infarcts. Splenectomy and cholecystectomy
were performed while chemotherapy induction continued
as scheduled. Four days later, he developed ischemic areas
in the kidneys and ischemic colitis in the sigmoid colon.
Hypercoagulation studies showed severe deficiency of
protein C. Tests showed protein C 16% (reference range
70–140%), protein S 87% (reference range 70–140%),
antithrombin III 122% (reference range 80–120%),
prothrombin time 13.6 s (referenceU11.3), INR
(international normalized ratio) 1.21, partial thromboplastin
time 33s (referenceU33), fibrinogen 214mg/dl, D-dimer
970mg/ml, factor II 98%, and that antinuclear antibody,
antiphospholipid antibodies, mutation for factor II gene
(G20210A), and mutation for Arg506 Gln of factor V were all
negative (factor V Leiden). There was no evidence of clinical
disseminated intravascular coagulation (DIC). He wasopyright © Lippincott Williams & Wilkins. Unautho
0957-5235  2011 Wolters Kluwer Health | Lippincott Williams & Wilkinstreated with low molecular weight heparin and did well. He
continues to be in complete remission 7 years later with
normal protein C levels. Acquired protein C deficiency can
occur in a variety of settings and has been reported in acute
myelocytic leukemia. However, clinically significant
thrombosis in the absence of clinical DIC, such as our case,
remains extremely rare. Blood Coagul Fibrinolysis 22:140–
143  2011 Wolters Kluwer Health | Lippincott Williams &
Wilkins.
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We report the case of a 6-year-old Lebanese boy who
presented with pallor associated with abdominal pain,
anorexia, and fatigue. Physical examination revealed
ecchymoses on his right lower calf, abdominal tender-
ness over the epigastric region, and slight hepatosple-
nomegaly. A complete blood count was performed upon
admission and showed a hemoglobin level of 10.2 g/dl,
hematocrit of 30.8%, platelet count of 32 103/ml, and
white blood cell count of 36.55 103/ml. Peripheral
smear showed 5% neutrophils, 8% lymphocytes, 81%
promyelocytes (1% are hypergranular and 80% are hypo-
granular), and 6% blasts. Liver function studies showed
serum glutamic pyruvic transaminase (SGPT) of 50U/l,
serum glutamic oxaloacetic transaminase (SGOT) of
11U/l, direct bilirubin of 0.3mg/dl, and total bilirubin
of 0.5mg/dl. Abdominal ultrasound at diagnosis
showed mild hepatosplenomegaly. Bone marrow aspira-
tion showed a hypercellular marrow massively invaded
by atypical hypogranular promyelocytes (93% of the
counted cells). Immunophenotyping showed positivity
for the following markers: CD13, CD33, CD45, CD64,and myeloperoxidase. Cells partially expressed CD14
and were negative for the expression of HLADR and
CD34. Results are consistent with acute promyelocytic
leukemia (AML-M3V). Molecular studies were positive
for t(15;17) PML/RAR-a fusion transcript and negative
for t(8;21) AML1/ETO, inv16RBF-b/MYH11, and
t(9;11)MLL/AF-9 fusion transcripts. Bonemarrow kary-
otype at diagnosis showed t(15;17) and complex chro-
mosomal abnormalities of chromosomes 1, 4, and 7 in all
cells studied: [46, XY, del(1)q(11), der(4)t(?1q;4p),
der(7)t(?1q;7q), t(15;17)(q22;q21)]. DNA index was
1.08. Cerebrospinal fluid was negative for malignant
cells.
Induction chemotherapy was administered according to
the AML-BFM 98 protocol consisting of continuous
infusion for 48 h (days 1, 2, and 3) of cytarabine
100mg/m2 and then 100mg/m2 every 12 h for 12 doses
(days 3 through 8) as well as etoposide 150mg/m2 (days 6,
7, and 8), idarubicin 12mg/m2 per day (days 3, 5, and 7),
and intrathecal cytarabine (days 1 and 8) along with
vesanoid 20mg orally twice daily from day 1 of induction.rized reproduction of this article is prohibited.
DOI:10.1097/MBC.0b013e32834248e6
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Fig. 1
The figure shows an enlarged spleen and hypodensities are seen in the
spleen except for a focus around the hilum. This implies that it is the
only focus that is irrigated, and the rest of the spleen is infarcted. Large
areas of decreased intensity are seen in the liver, which can signify
irregular fatty liver infiltrates.
Fig. 2
The figure shows evidence of an infarcted spleen. Severe edema of the
porta hepatis is also identified.
Fig. 3
The figure shows evidence of an infarcted spleen as well as severe
edema of the gallbladder.On the sixth day of induction, he developed increasing
abdominal pain. A computed tomography (CT) scan of
the abdomen and pelvis with intravenous contrast
revealed an infarct involving most of the spleen and
evidence of fatty infiltrates in the liver (Fig. 1). Severe
edema of the gallbladder and porta hepatis was also
identified, which is suspicious of a gallbladder infarct
(Figs 2 and 3). The splenic infarct was confirmed
by nuclear scan, which showed no uptake in the spleen.
Liver function studies at that time were within normal
limits; however, albumin levels were found to be
mildly decreased to 2.9 g/dl. A splenectomy and a
cholecystectomy were performed. The spleen was
completely infarcted and the gallbladder had multiple
areas of necrosis. He received one dose of pneumo-
coccal vaccine 1 day before the operation. The post-
operative course was uneventful and he improved
considerably.
On postoperative day 10 (day 16 from the start of induc-
tion), the patient experienced new onset of postprandial
abdominal pain associated with fever, and severe diar-
rhea. A repeat CT scan of the abdomen showed an area of
wedge infarct in the left kidney (Fig. 4) and evidence of
ischemic colitis in the sigmoid colon (Fig. 5). A colono-
scopy was performed showing edema of the mucosa with
superficial ulceration in the sigmoid colon. The patient
was treated conservatively. He was started on low mol-
ecular weight heparin (LMWH), 40mg q24h on day 21
from the start of induction for a duration of 10 days.
The dose was then augmented to 60mg q24h and wasopyright © Lippincott Williams & Wilkins. Unauthmaintained for another 10 days. Factor Xa levels were
followed. He was then discharged home on LMWH
subcutaneously for a total of 3 months.
Hypercoagulation studies were performed (on day 23
after the start of induction, 8 days after end of induction)
and revealed a notable deficiency in protein C activity.
Tests yielded the following results: protein C 16%
(reference range 70–140%), protein S 87% (reference
range 70–140%), activated protein C (APC) ratio 1.76
(normal¼ 2–3.5, heterozygote¼ 1.7, homozygote¼ 1.2),
antithrombin III 122% (reference range 80–120%),
prothrombin time (PT) 13.6 s (reference¼ 11.3),
international normalized ratio (INR) 1.21, partialorized reproduction of this article is prohibited.
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Table 1 Serial measurements of fibrinogen and D-dimer
9/13/2002 9/27/2002 11/26/2002 21/23/2002
D-dimer (mg/ml) 970 200 200 220
Fibrinogen (mg/dl) 214 247 302 391
Fig. 4
The figure shows a wedge infarct in the posterior part of the left kidney.thromboplastin time (PTT) 33 s (reference¼ 33), fibrino-
gen 214mg/dl (normal range¼ 200–400mg/dl), D-dimer
970mg/ml, antinuclear antibody (ANA) was negative,
antiphospholipid antibodies were negative, factor II
98%, mutation for factor II gene (G20210A) was negative,
and mutation for Arg506 Gln of factor V was negative
(factor V Leiden). There was no family history of throm-
botic diseases. Family studies revealed normal protein C
levels in both parents. Fibrinogen levels were repeated
on several occasions and had shown steady levels
throughout the course of the disease (Table 1).opyright © Lippincott Williams & Wilkins. Unautho
Fig. 5
The figure shows thickening of the bowel walls. The wall of sigmoid
colon is thickened, and evidence of dense fat is seen, which is
suggestive of mesenteric infarct.The protein C activity assay was performed on a
STA coagulation analyzer using the STA-staclot Protein
C kit (Diagnostica Stago, Asnieres-sur-Seine, France).
The protein S activity assay was performed on a STA
coagulation analyzer using the STA-staclot Protein S kit
(Diagnostica Stago).
Determination of antithrombin III was done using
chromogenic tests, COAMATIC Antithrombin (Chromo-
genix Instrumentation Laboratory, Milan, Italy).
Antiphospholipid screen was performed using ORGEN-
TEC Anti-Phospholipid Screen IgG/IgM assay
(ORGENTEC Diagnostika GmbH, Mainz, Germany).
Determination of possible factor V mutation was done
using HemosIL factor V Leiden [(APC Resistance V) –
0020008700 (Instrumentation Laboratory Company,
Lexington, Massachusetts, USA)].
He went into complete remission and continued his
chemotherapy as scheduled. Protein C levels returned
to normal 33 days after the end of induction.
The patient was followed up on a yearly basis for 7 years
after his initial treatment. Results showed that he was still
in complete remission with normal protein C levels
throughout the 7 years.
Discussion
Protein C is a vitamin K-dependent protein synthesized
in the liver. It circulates as a zymogen and exerts its
anticoagulant function after activation to the serine pro-
tease, APC. The primary effect of APC is to decrease the
coagulation activity of factors Va and VIIIa, which are
necessary for efficient factor X activation and thrombin
generation [1]. Low plasma APC levels have been associ-
ated with an increased risk of venous thromboembolism
[2,3]. Acquired deficiency can occur in a variety of set-
tings, including liver disease, severe infection, septic
shock, disseminated intravascular coagulation (DIC),
acute respiratory distress syndrome, and breast cancer
patients receiving cyclophosphamide, methotrexate, and
5-fluorouracil, and in association with L-asparaginase
therapy [4–7].
Thromboembolic events are common in leukemia
patients and are usually attributed to a concurrent state
of DIC. Tsumita et al. [8] reported a patient with acute
myelocytic leukemia (AML), multiple thrombophlebitis,
and DIC accompanied with lower protein C activity and
antigen levels. All parameters had returned to normal
after complete remission. As such, protein C deficiencyrized reproduction of this article is prohibited.
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unknown factors released from leukemic cells. Cases of
patients showing thrombotic events in the absence of
DIC were also reported in whom coagulation studies
were performed showing a decrease in free protein C
levels. Maureen et al. [9] described a patient with chronic
lymphocytic leukemia, AML, and protein C deficiency,
who developed deep vein thrombosis of the calf. The
patient had no evidence of liver dysfunction, DIC, or
family history of protein C deficiency; however, there was
a strong family history suggestive of hypercoagulability.
Low protein C, S, and antithrombin III have also been
reported in a series of leukemia patients, mainly with
AML-M3. In this series, thrombotic complications
coinciding with AML and protein C deficiency were only
reported in one AML-M3 patient in the form of myo-
cardial infarction at day 15 of induction. In that study, the
significance of their observation in terms of predisposi-
tion to thrombosis or DIC was not established [10].
Protein C deficiency has been reported in several
AML cases in the absence of DIC, but without significant
thrombotic events. Rodeghiero et al. [11] reported slightly
lower levels of protein C and antithrombin III in acute
leukemia patients. Protein C levels were not lower in
patients with DIC when compared to patients without
DIC. A close correlation was noted between the levels of
these inhibitors and the synthetic function of the liver as
expressed by indices such as serum albumin and pseu-
docholinesterase levels. As such, liver dysfunction rather
than DIC was considered to be the cause of decreased
anticoagulants. Troy et al. [12] reported low levels of
protein C antigen and protein C activity in 50 patients
with acute leukemia (34 acute myelogenous leukemia
and 16 acute lymphoblastic leukemia). In that study, no
correlation was made between protein C levels and liver
dysfunction. There were no thrombotic events due to
protein C deficiency; thrombotic events occurred only in
three patients who had developed DIC.
In the present case, there was no evidence of clinical
DIC, infection, or shock, and the chemotherapy agents
used for treatment of this case of AML-M3 are not known
to induce a hypercoagulable state. As it seems, the patient
had developed protein C deficiency along the course of
his AML. Consequently, the patient developed splenic,
mesenteric, and renal infarction. The cause of protein C
deficiency remains unclear. When compared with
previous literature, one can postulate that deficiency
may have been caused by liver dysfunction as evidencedopyright © Lippincott Williams & Wilkins. Unauthby fatty infiltrate of the liver seen on CT scan of the
abdomen, demonstrating possible inflammatory reactions
and a mild decrease in albumin levels at the time of
protein C deficiency, although liver enzymes remained
normal throughout the course of the disease.
The development of protein C deficiency in an AML
patient resulting in significant intra-abdominal organ
ischemia has rarely been reported. Physicians should
be aware of this potential complication. Early diagnosis
and management in order to avoid further complications
is extremely important. Considering the possibility of
treatment with APC concentrate should be investigated
in the future.
Acknowledgements
The authors would like to acknowledge Dr Anthony
Chan, Dr Khaled Musallam, and Dr The´re`se Abi-Nasr
for their comments and their critical review of the article.
References
1 Griffin JH. Control of coagulation reactions. In: Beutler E, Lichtman MA,
Coller BS, Kipps TJ, Seligsohn U, editors. Williams hematology. 6th ed.
New York: McGraw Hill Inc.; 2001. p. 1436.
2 Espanˇa F, Vaya´ A, Mira Y, Medina P, Estelle´s A, Villa P, et al. Low level of
circulating activated protein C is a risk factor for venous thromboembolism.
Thromb Haemost 2001; 86:945–948.
3 Olson J, Steuber P, Hawkins E, Mahoney D. Functional deficiency of protein
C associated with mesenteric venous thrombosis and splenic infarction.
Am J Pediatr Hematol Oncol 1991; 13:168–171.
4 Bezeaud A, Drouet L, Leverger G, Griffin JH, Guillin MC. Effect of L-
asparaginase therapy for acute lymphoblastic leukemia on plasma vitamin
K-dependent coagulation factors and inhibitors. J Pediatr 1986; 108:698–
701.
5 Conard J, Horellou MH, Van Dreden P, Potevin F, Zittoun R, Samama M.
Decrease in protein C in L-asparaginase-treated patients. Br J Haematol
1985; 59:725–727.
6 Rogers JS II, Murgo AJ, Fontana JA, Raich PC. Chemotherapy for breast
cancer decreases plasma protein C and protein S. J Clin Oncol 1988;
6:276–281.
7 Feffer SE, Carmosino LS, Fox RL. Acquired protein C deficiency in patients
with breast cancer receiving cyclophosphamide, methotrexate, and 5-
fluorouracil. Cancer 1989; 63:1303–1307.
8 Tsumita Y, Matsushima T, Uchiumi H, Narahara N, Tamura J, Karasawa M,
et al. Acute myeloid leukemia accompanied by multiple thrombophlebitis.
Intern Med 1997; 36:595–597.
9 Maureen G, Conlan M, Mosher D. Concomitant chronic lymphocytic
leukemia, acute myeloid leukemia, and thrombosis with protein C
deficiency. Cancer 1989; 63:1398–1401.
10 Dixit A, Kannan M, Mahapatra M, Choudhry V, Saxena R. Roles of protein C,
protein S, and antithrombin III in acute leukemia. Am J Hematol 2006;
81:171–174.
11 Rodeghiero F, Mannucci PM, Vigano S, Barbui T, Gugliotta L, Cortellaro M,
et al. Liver dysfunction rather than intravascular coagulation as the main
cause of low protein C and antithrombin III in acute leukemia. Blood 1984;
63:965–969.
12 Troy K, Essex D, Rand J, Lema M, Cuttner J. Protein C and S levels in acute
leukemia. Am J Hematol 1991; 37:159–162.orized reproduction of this article is prohibited.
